Treatment of Hidradenitis Suppurativa with Tumour Necrosis Factor-alpha Inhibitors

Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors.

Hidradenitis suppurativa (HS) is a common inflammatory skin disease. Medical treatment is often disappointing and in severe disease surgery remains the therapy of choice. Extensive surgery may be effective but also mutilating. Patients experience a significant reduction in quality of life and the need for new treatment modalities are urgent. In recent years patients with HS have been treated of...

Treatment of hidradenitis suppurativa with etanercept injection.

OBJECTIVES To observe the effects of etanercept treatment on the cutaneous manifestations of hidradenitis suppurative (HS) and to evaluate physician and patient global assessment scores of cutaneous manifestations. DESIGN Single-center, randomized, prospective, double-blind, placebo-controlled study. SETTING Academic dermatology practice. PATIENTS Twenty patients with active moderate to s...

Hidradenitis suppurativa: a treatment challenge.

Hidradenitis suppurativa is a chronic, recurrent, debilitating disease that presents with painful, inflamed lesions in the apocrine-gland-bearing areas of the body, most commonly the axillary, inguinal, and anogenital areas. Etiology traditionally has been attributed to occlusion of the apocrine duct by a keratinous plug; however, defects of the follicular epithelium also have been noted. Contr...

[Hidradenitis suppurativa. Response to treatment with infliximab].

INTRODUCTION Hidradenitis suppurativa is a chronic inflammatory disease that runs in outbreaks with painful lesions, fistulas and scars in axillae, groins, buttocks, and perianal and submammary regions. Among multiple drug therapies available, infliximab, usually employed in dermatology to control psoriasis, has shown its efficacy in the past five years. PATIENTS AND METHOD It is a prospectiv...

Tumour necrosis factor alpha inhibitors for the treatment of adult rheumatoid arthritis